Namilumab (mono ab to GM-CSF, Granulocyte-macrophage colony-stimulating factor) with good efficacy among MTX/TNF inadequate responders in a phase II RCT. NNT = 3-4 at week 12 for ACR50 at max dose. Some respiratory ADE but nothing major. https://t.co/hwHDFqCqOq https://t.co/XPsc4fjsXx